OPCH stock forecast, quote, news & analysis
Option Care Health Inc is the provider of home and alternate-site infusion services... Show more
Why Option Care Health (OPCH) Is Down -26% in the Last 30 Days
Key Takeaways
- OPCH stock tumbled 26% over the past 30 days amid a sharp post-earnings selloff triggered by a Q1 revenue miss and supply chain disruptions from Hurricane Helene.
- The quarterly performance showed a steeper 42% decline, reflecting decelerating revenue growth and broader market concerns over execution.
- Q1 revenue grew just 1.3% year-over-year to $1.35 billion, missing estimates, while adjusted EPS held flat at $0.40.
- Guidance for FY2026 projects modest revenue expansion of about 4% at the midpoint, signaling ongoing challenges in re-accelerating growth.
- Supply constraints on intravenous solution bags contributed to the revenue shortfall, highlighting vulnerabilities in the home infusion supply chain.
- Analyst sentiment remains mixed, with recent price target reductions but a consensus "Moderate Buy" rating.
Option Care Health (OPCH) Company Overview and Market Position
Option Care Health, Inc. is the nation's largest independent provider of home and alternate site infusion services in the United States. The company delivers a broad range of therapies, including anti-infective treatments, parenteral nutrition, and immunoglobulin therapy, primarily to patients with chronic and acute conditions. Its business model revolves around clinical expertise, nationwide scale, and partnerships with payers and healthcare providers to deliver cost-effective care outside traditional hospital settings.
In the competitive home infusion industry, Option Care Health holds a leading position through its extensive network of accredited pharmacies and focus on complex therapies. This exposure to specialty pharmaceuticals and home-based care explains recent stock price sensitivity to reimbursement dynamics, supply chain reliability, and demand for high-cost infusions, which have faced headwinds from slower growth and external disruptions.
Option Care Health (OPCH) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, OPCH stock declined -26%, moving from a close of $26.92 to approximately $19.83. The price action was volatile, trading in a 26-29 range early in the period before a sharp post-earnings plunge on April 30 amid heavy volume.
For the past quarter, the stock fell -42%, from around $34.00 to $19.83. The movement featured an early peak near $36, followed by a steady downtrend through March and April, characterized by range-bound trading punctuated by selling pressure on weaker-than-expected updates.
What Drove OPCH Stock Price in the Last 30 Days
The primary catalyst for OPCH's 30-day downturn was the Q1 2026 earnings release, which revealed revenue of $1.351 billion, up only 1.3% year-over-year and below analyst expectations. While GAAP EPS rose 3.6% to $0.29 and adjusted EPS matched $0.40, the modest top-line growth disappointed investors seeking re-acceleration. Management attributed the shortfall partly to Hurricane Helene-related disruptions in the supply chain for intravenous solution bags, a critical input for infusion services.
The stock reacted swiftly, dropping 14.4% immediately post-earnings before further pressure. Elevated implied volatility ahead of the report amplified the move, reflecting uncertainty around supply issues and growth trajectory. Prior to earnings, shares traded steadily around prior lows, supported by a "Moderate Buy" consensus but weighed by cautious sentiment.
What Drove OPCH Stock Performance Over the Last Quarter
OPCH's quarterly decline stemmed from sustained concerns over decelerating revenue growth, shifting from double-digit rates in prior periods to low single digits in Q1. The stock peaked in mid-January near $36 amid optimism for infusion demand but trended lower as macroeconomic pressures on healthcare spending and reimbursement rates emerged.
Broader industry developments, including supply vulnerabilities exposed by weather events, compounded the pressure. Analyst actions, such as Argus lowering its target to $26, signaled tempered expectations. Institutional flows and sector rotation away from healthcare services contributed to the downtrend, with the stock range-bound in March before accelerating lower into April. Cumulative impacts from softer demand narratives and execution risks dominated the period's price movement.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the top-performing AI trading bots from its extensive library of hundreds of algorithms actively trading thousands of tickers across various markets. These curated bots represent the most relevant and high-performing strategies based on recent metrics like win rate, average return, and consistency. Strategies range from momentum and mean reversion to pattern recognition, spanning short-term day trades to longer-term swings. Performance data is transparently displayed, allowing users to filter by timeframe, risk level, and asset class. Explore Trending AI Robots to discover automated tools tailored to current market trends and potentially enhance your trading approach.
OPCH Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor resolution of intravenous supply chain issues post-Hurricane Helene, as normalization could support revenue recovery. Upcoming Q2 earnings will provide updates on execution of growth initiatives and FY2026 guidance progress. Industry trends in home infusion demand, particularly for specialty therapies like immunoglobulins, remain key amid reimbursement changes. Macro factors such as interest rates and healthcare policy shifts could influence sentiment. Strategic developments in partnerships or clinic expansions, alongside any M&A (mergers and acquisitions) activity, warrant attention. Risks include prolonged supply disruptions and competitive pressures in alternate site care.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
OPCH in upward trend: price expected to rise as it breaks its lower Bollinger Band on April 29, 2026
OPCH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 37 cases where OPCH's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where OPCH advanced for three days, in of 301 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on April 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OPCH as a result. In of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for OPCH turned negative on April 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .
The 50-day moving average for OPCH moved below the 200-day moving average on April 27, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OPCH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for OPCH entered a downward trend on May 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.289) is normal, around the industry mean (136.653). P/E Ratio (15.391) is within average values for comparable stocks, (101.220). Projected Growth (PEG Ratio) (1.107) is also within normal values, averaging (2.432). Dividend Yield (0.000) settles around the average of (0.036) among similar stocks. P/S Ratio (0.560) is also within normal values, averaging (2.406).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. OPCH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OPCH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of home and alternate site infusion services.
Industry HospitalNursingManagement